Wechselwirkungen · Epidyolex
Epidyolex 100 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 8
HOS-140617 · Präparat HOS-098554
Everolimus Coadministration of cannabidiol (12.5 mg/kg twice daily) with the P-gp and CYP3A4 substrate everolimus (5 mg) in a healthy volunteer study led to an increase in everolimus exposure of approximately 2.5-fold for both Cmax and AUC. The mechanism for this interaction is believed to be inhibition of intestinal P-gp efflux, leading to increased bioavailability of everolimus, because cannabidiol did not affect midazolam exposure in another interaction study. The half-life of everolimus was not affected, confirming the lack of systemic inhibitory effects of cannabidiol on P-gp and CYP3A4 activity. When initiating cannabidiol in patients taking everolimus, monitor therapeutic drug levels of everolimus and adjust the dose accordingly. When initiating everolimus in patients taking a stable dose of cannabidiol, a lower starting dose of everolimus is recommended, with therapeutic drug monitoring.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): everolimus (HOS-086310) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:14:00Z · SHA-256 ccb7fce36b37a5c512676c2475ea9ab250d2fd66d8e1f76a5048e693726825e9 · Passage 8b9faecee792b581463b295cf2dba4d1d3683cb0ea796e35cccb58317ac6928a · Zeichen 3788–4696 im Abschnitt